SCHEMBL25613050

SCHEMBL25613050

CC(C)(C)c1cc2cc[nH]c2nc1OCCO

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FEN1 P39748 2/20 0.39
▸ CDK8 P49336 9/20 0.38
▸ RIPK1 Q13546 1/20 0.35
▸ KDR P35968 2/20 0.35
▸ BRD4 O60885 2/20 0.35
▸ FGFR1 P11362 1/20 0.35
▸ AXL P30530 1/20 0.34
▸ GAA P10253 1/20 0.33
▸ PLK4 O00444 1/20 0.33
▸ DCLK1 O15075 1/20 0.33
▸ ROCK2 O75116 1/20 0.33
▸ PRKD3 O94806 1/20 0.33
▸ MAP4K4 O95819 1/20 0.33
▸ PAK4 O96013 1/20 0.33
▸ CHEK2 O96017 1/20 0.33
▸ INSR P06213 1/20 0.33
▸ CDK1 P06493 1/20 0.33
▸ FES P07332 1/20 0.33
▸ ROS1 P08922 1/20 0.33
▸ PDGFRB P09619 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25613335 0.89 FEN1 (0.39) FEN1CDK8RIPK1KDRBRD4
SCHEMBL25613045 0.86 ULK1 (0.39) FEN1CDK8KDRBRD4FGFR1
SCHEMBL25613057 0.85 KDM4E (0.39) FEN1CDK8KDRBRD4FGFR1
SCHEMBL25613037 0.84 FEN1 (0.39) FEN1CDK8RIPK1KDRBRD4
SCHEMBL25613056 0.84 KDM4E (0.39) FEN1KDRFGFR1GAAROCK2
SCHEMBL24005743 0.81 CDK8 (0.40) CDK8RIPK1KDRBRD4FGFR1
SCHEMBL25613047 0.81 KDR (0.39) FEN1CDK8RIPK1KDRBRD4
SCHEMBL25613043 0.81 CDK1 (0.39) FEN1CDK8KDRBRD4FGFR1
SCHEMBL25613035 0.81 ULK1 (0.39) FEN1CDK8KDRBRD4FGFR1
SCHEMBL24005904 0.80 CDK8 (0.39) FEN1CDK8RIPK1KDRBRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159527-A1 COMPOUNDS AS BCL-2 INHIBITORS FOCHON BIOSCIENCES, LTD. (CN) 2023-05-25 — — US disclosed
US-20230159527-A1 COMPOUNDS AS BCL-2 INHIBITORS FOCHON BIOSCIENCES, LTD. (CN) 2023-05-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159527-A1 COMPOUNDS AS BCL-2 INHIBITORS BCL2, BCL2L2, BCL2L1 FEN1 1864/4885CDK8 533/4885RIPK1 1106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback